TABLE 3.
Analysis | n | Estimate*
|
(between-patient variance)† | (within- patient variance)† | (ICC) † | ||
---|---|---|---|---|---|---|---|
Bone | Lung | Soft tissue or lymph node | |||||
Analysis | |||||||
18F-fluoroestradiol mean SUVLBM | 505 | 1.07 (0.83–1.38) | 0.95 (0.64–1.41) | 0.79 (0.61–1.04) | 0.73 | 0.49 | 0.60 (0.50–0.69) |
18F-FDG maximum SUVLBM | 492 | 2.88 (2.43–3.40) | 2.01 (1.50–2.70) | 2.32 (1.94–2.78) | 0.30 | 0.25 | 0.54 (0.44–0.64) |
18F-fluoroestradiol maximum /18F-FDG maximum ratio | 492 | 0.74 (0.57–0.93) | 0.69 (0.43–0.99) | 0.66 (0.49–0.86) | 0.06 | 0.03 | 0.65 (0.56–0.73) |
| |||||||
With alternate PET measures | |||||||
18F-fluoroestradiol maximum SUVLBM | 505 | 1.92 (1.57–2.34) | 1.38 (1.00–1.90) | 1.42 (1.15–1.75) | 0.43 | 0.33 | 0.57 (0.47–0.66) |
18F-fluoroestradiol mean SUV | 505 | 1.60 (1.23–2.08) | 1.39 (0.92–2.10) | 1.16 (0.88–1.54) | 0.80 | 0.51 | 0.61 (0.51–0.70) |
18F-fluoroestradiol maximum SUV | 505 | 2.88 (2.33–3.55) | 2.02 (1.45–2.80) | 2.11 (1.69–2.63) | 0.50 | 0.33 | 0.60 (0.51–0.69) |
18F-FDG maximum SUV | 492 | 4.31 (3.62–5.13) | 2.92 (2.17–3.94) | 3.44 (2.86–4.14) | 0.33 | 0.25 | 0.56 (0.46–0.66) |
Transformed from log2 (18F-fluoroestradiol, 18F-FDG) or square root (ratio) scale used in model.
Log2 (18F-fluoroestradiol, 18F-FDG) or square root (ratio) scale.
Data in parentheses are 95% CIs. Estimates shown are for patients with advanced disease and 1–3 lesions.